<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819271</url>
  </required_header>
  <id_info>
    <org_study_id>CXL-1427-01</org_study_id>
    <secondary_id>CV013-005</secondary_id>
    <nct_id>NCT02819271</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers</brief_title>
  <official_title>A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardioxyl Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by percentage of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 31 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability measured by percentage of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 31 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steady-state plasma concentration (Css)</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration (AUC) vs. time curve</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (1/2)</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state volume of distributions (Vss)</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Css</measure>
    <time_frame>Up to 4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CXL-1427 (BMS-986231)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXL-1427 Ascending Dose</intervention_name>
    <arm_group_label>CXL-1427 (BMS-986231)</arm_group_label>
    <other_name>BMS-986231</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXL-1427 Descending Dose</intervention_name>
    <arm_group_label>CXL-1427 (BMS-986231)</arm_group_label>
    <other_name>BMS-986231</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No evidence of any acute or chronic health disorder

          -  Not have taken any prescription medication within 15 days of study entry

          -  Not have taken any over-the-counter medication or herbal/vitamin supplement within 3
             days of study entry

          -  Not have not have any dietary restrictions

          -  Have a body mass index (BMI) of ≥18 to ≤34

          -  Weigh at least 50kg (110 pounds)

        Exclusion Criteria:

          -  Be a current or recent (within 6 months of the Screening Visit) smoker or user of any
             nicotine-containing product

          -  Have a history of symptomatic hypotension, orthostatic hypotension or syncope

          -  Have a history of headaches or other symptoms attributable to caffeine withdrawal

          -  Have a history of any bleeding diathesis

          -  Have a positive serology screen for HIV antibody, hepatitis B surface antigen or
             hepatitis C antibody at screening

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cardioxyl Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Cardioxyl Pharmaceuticals</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

